Phio Pharmaceuticals reports Q3 2026 results and advances PH‑762 toward Phase 2b
Phio Pharmaceuticals announced its third‑quarter 2026 financials and a business update. The company completed commercial‑scale manufacturing of its PH‑762 drug substance, submitted a full Phase 1b clinical report to the FDA and seeks feedback by the end of November 2026. A Phase 2b neoadjuvant study in cutaneous squamous‑cell carcinoma is slated to start in the first quarter of 2027.
Why it matters
The cash balance fell to $10.6 million as of September 30, 2026, down from $21.0 million at year‑end 2025, reducing the runway for the PH‑762 program (the company’s lead candidate). The increase in R&D spending and the upcoming Phase 2b trial may pressure cash further, prompting investors to monitor future financing needs.
Key facts
- 1Cash and cash equivalents were $10.6 million on September 30, 2026, compared with $21.0 million on December 31, 2025. sec.gov
- 2R&D spending for the quarter ended September 30, 2026 totaled $3.0 million, an increase of $1.9 million (159%) versus the same quarter in 2025. sec.gov
- 3R&D expenses for the nine months ended September 30, 2026 were $8.9 million, up $5.8 million (180%) from the prior year period. sec.gov
- 4General and administrative costs for the quarter were $1.2 million, $100 thousand (9%) lower than the comparable quarter in 2025. sec.gov
- 5The Phase 1b trial enrolled 22 patients (20 with cutaneous squamous‑cell carcinoma, 1 with melanoma, 1 with Merkel cell carcinoma) and was completed in June 2026. sec.gov
- 6The company released its first commercial‑scale cGMP batch of PH‑762 drug substance in Q3 2026. stocktitan.net
Summary written by AlphAI AI Desk from 5 of 5 sources. Not investment advice. Figures are as stated by the linked sources.